Browse by author
Lookup NU author(s): Dr Pasquale RescignoORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2024 Informa UK Limited, trading as Taylor & Francis Group.Aim: To define the prognostic significance of first-line TKI in mRCC patients receiving nivolumab. Materials and methods: A total of 571 mRCC patients who received ≥second line nivolumab were included in this subanalysis. The correlation between prior TKI (sunitinib vs. pazopanib) and overall response rate (ORR), disease control rate, progression-free survival and overall survival were investigated. Additionally, the impact of TKI choice according to the International Metastatic RCC Database Consortium prognostic score was examined. Results: There was no significant difference between sunitinib and pazopanib groups in terms of mPFS, mOS, overall response rate and disease control rate. Moreover, no difference between sunitinib and pazopanib was found according to the International Metastatic RCC Database Consortium prognostic score. Conclusion: There is no conclusive evidence favoring pazopanib or sunitinib treatment before initiating nivolumab therapy in metastatic renal cell carcinoma patients.
Author(s): Damassi A, Cremante M, Signori A, Rebuzzi SE, Malgeri A, Napoli MD, Caffo O, Vignani F, Cavo A, Roviello G, Prati V, Tudini M, Atzori F, Messina M, Morelli F, Prati G, Nole F, Catalano F, Murianni V, Rescigno P, Banna GL, Fornarini G, Buti S
Publication type: Article
Publication status: Published
Journal: Immunotherapy
Year: 2024
Pages: epub ahead of print
Online publication date: 19/08/2024
Acceptance date: 25/07/2024
ISSN (print): 1750-743X
ISSN (electronic): 1750-7448
Publisher: Taylor and Francis Ltd.
URL: https://doi.org/10.1080/1750743X.2024.2385881
DOI: 10.1080/1750743X.2024.2385881
Altmetrics provided by Altmetric
